肇民科技(301000.SZ):簽署《投資框架協議》
格隆匯5月23日丨肇民科技(301000.SZ)公佈,擬與肇產業株式會社(英文名:HAJIMEINDUSTRYCO.LTD)、平民三(英文名:TAMIZOTAIRA)、HAJIMEPRECISIONPLASTICPRODUCTDEMEXICO(簡稱“目標公司”)簽署《投資框架協議》,公司或其境外全資子公司擬以增資及受讓股份相結合的方式取得目標公司70%的股份表決權及分紅權。本協議的簽署旨在充分發揮各方優勢,實現資源互補,拓展公司海外業務與提升市場競爭力,同時也有利於提高公司盈利的能力,增強公司抵禦風險的能力,發揮良好的協同效應,符合公司整體發展戰略以及公司業務發展需要。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.